Alkegen Backed by Clearlake Capital, Announces New Aerogel Technology
Alkegen, a leading specialty materials platform creating transformational materials, today introduced its latest proprietary technology, AlkeGel™ by Alkegen. AlkeGel is a next generation flexible aerogel material designed for electric vehicle and battery fire protection applications, along with other industrial thermal management uses. AlkeGel from Alkegen offers exceptionally low thermal conductivity and dustiness, superior thermal performance and a reduction in insulation thicknesses compared to competing insulation products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005730/en/
AlkeGel is Alkegen’s first step into fiber-based aerogel composite materials for critical applications in battery and electric vehicle safety, fire protection and industrial thermal management segments. Alkegen is the new company launched in January following the acquisition of Lydall Materials by Unifrax. Alkegen is a one-of-a-kind specialty materials platform dedicated to human health and sustainability. Alkegen is a global leader in transformative high growth battery technologies, filtration media and specialty insulation with a deep history of vertically integrated manufacturing at large scale to provide solutions for advanced industries including electric vehicles, filtration, aerospace, and chemical processing. The company expects production for AlkeGel materials to come online in mid-2022 with plans to build thousands of tons of long-term manufacturing capacity.
”AlkeGel is the latest development from our long-standing tradition of innovating unique material technologies to create superior new products and solutions for our customers’ greatest challenges,” explained Chad Cannan, Senior Vice President and Chief Innovation Officer at Alkegen. “These composite aerogel materials offer excellent insulation properties, and include advanced proprietary technology features we’ve developed with our novel aerogel process. AlkeGel creates performance advantages for our customers in terms of improved product handling, a wide range of shapes and sizes and step change EV fire safety relative to other high performance insulations on the market today. Alkegen’s AlkeGel technology coupled with the broadest set of large scale global end product forming and finishing operations marks a new horizon for these exciting materials,” said Cannan.
“This transformational aerogel portfolio presents numerous opportunities for Alkegen with applications spanning EV lithium ion battery protection, cryogenic applications along with the broader industrial and fire protection markets. AlkeGel products add to our complete portfolio of robust electric vehicle and battery solutions which include AGM separator materials, novel silicon anode materials, lithium ion glass separators, interstitial thermal runaway barriers, and battery compartment fire protection systems,” added John Dandolph, President and CEO of Alkegen.
Alkegen will be available to discuss their innovative new aerogel materials during the 2022 AABC Europe Show June 13, in Mainz, and The Battery Show June 28, in Stuttgart, Germany. Interested attendees can sign up for sessions with our Alkegen Battery Group experts to meet during the conferences by contacting us at info@alkegen.com.
About Alkegen
Alkegen, formerly Unifrax and Lydall Materials, creates high performance specialty materials used in advanced applications including electric vehicles, energy storage, filtration, fire protection and high-temperature insulation, among many others. Alkegen products are designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our mission of helping the world breathe easier, live greener and go further than ever before. Alkegen has 75 manufacturing facilities operating in 12 countries and employs 9,000+ employees globally. More information is available at www.alkegen.com.
About Clearlake
Clearlake Capital Group, L.P. is an investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $30 billion of assets under management and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005730/en/
Contact information
Media:
For Alkegen:
Deborah L. Myers
Director, Marketing Communication
dmyers@alkegen.com
716.768.6465
For Clearlake:
Jennifer Hurson
jhurson@lambert.com
845-507-0571
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models5.1.2026 15:54:00 EET | Press release
The Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced the release of Falcon H1R 7B, a next-generation AI model that takes a significant step toward making advanced AI more accessible than ever, by delivering world-class reasoning performance in a compact, efficient, and openly available format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105981339/en/ TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models (Graphic: AETOSWire) With just 7 billion parameters, Falcon H1R 7B challenges and, in many cases, outperforms larger open-source AI models from around the world, including models from Microsoft (Phi 4 Reasoning Plus 14B), Alibaba (Qwen3 32B), and NVIDIA (Nemotron H 47B). This model release reaffirms TII’s position at the forefront of efficient AI innovation and reinforces the UAE’s growing influ
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 15:00:00 EET | Press release
Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evaluated as presenting the true 'Gold Standard' in regenerative medicine by perfectly resolving the inherent challenges—such as immune rejection, incomplete reprogramming, and the inheritance of aging—that have been cited as limitations of existing stem cell therapies. Clonell's SCNT technology establishes a patient-specific embryonic stem cell line by transferring the nucleus of a patient's somatic cell into a healthy enucleated oocyte. This process
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi ® /Minjuvi ® ) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 14:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age. The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; p-value 0.019), according to Lugano 2014 criteria. The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed. “The frontMIND stud
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 14:30:00 EET | Press release
Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP. “Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 14:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. “This is an important milestone toward our goal of addressing critical gaps that patients living with polycythemia vera face today,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “The comprehensive VERIFY study data underscore rusfertide’s strong clinical profile and potential to provide sustained hematocrit control while reducing phlebotomy and symptom burden. Our collaboration with Protagonist exemplifies how partnerships can advance innovative science, with a focus on m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom